BioWorld - Sunday, December 15, 2019

Deals and M&A
%{topic} RSS Feed RSS

Deal-puzzle-pieces

ICU Medical buys Pursuit Vascular to gain first device to reduce hemodialysis infections

November 6, 2019
By Stacy Lawrence
No Comments
San Clemente, Calif.-based ICU Medical Inc. has acquired Minneapolis-based Pursuit Vascular Inc. for $75 million and an additional, undisclosed earn-out payment that would be due in 2021. In the deal, it gains the Clearguard HD Antimicrobial Barrier Cap, which is the only U.S.-marketed device that's been shown to reduce central line-associated bloodstream infections in hemodialysis patients.
Read More
Cancer-stem-cells

Allogene inks exclusive IPSC deal with Canada's Notch Therapeutics

November 6, 2019
By Michael Fitzhugh
No Comments
Allogene Therapeutics Inc., a South San Francisco-based company developing off-the-shelf allogeneic T-cell therapies for cancer, is taking a 25% stake in Notch Therapeutics Inc., paying the Canadian startup $10 million up front in an exclusive deal to research and develop new induced pluripotent stem cell (IPSC)-based CAR T therapies. The partners will initially focus on developing next-generation treatments for non-Hodgkin lymphoma (NHL), leukemia and multiple myeloma.
Read More
Acquisition-fish.png
One of the largest med-tech deals of 2019

Speculation proves correct as Stryker agrees to hefty $5B buy of Wright Medical

November 5, 2019
By Liz Hollis
No Comments
Stryker Corp. is making another big buy, this time picking up Wright Medical Group NV, of Amsterdam, for a total enterprise value of about $5.4 billion. The deal is expected to close in the second half of 2020, and its value exceeds Stryker's previous large deal – that of Leesburg, Va.-based K2m Group Holdings Inc. in 2018 for $1.4 billion.
Read More

X rated: Roche endorsing Dicerna's genetic theory, potential $1.47B-plus tie

November 1, 2019
By Randy Osborne
No Comments
RNAi specialist Dicerna Pharmaceuticals Inc.'s chief operating officer, James Weissman, told BioWorld that scientists inside and outside of the company have come to believe in what's called "the X hypothesis" in hepatitis B virus (HBV). "My view, though, as a person who has been in the pharmaceutical industry for decades, is who cares, anyway?" he said – as long as the drug works. He pointed out that, with the cholesterol therapy Lipitor (atorvastatin calcium) from New York-based Pfizer Inc., where he served in business development and marketing, "everybody had a different theory for why it lowered the incidence of heart disease. Nobody knew with certainty."
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe